OKYO Pharma Limited (NASDAQ: OKYO) Stock Information | RedChip
OKYO PHARMA LIMITED NASDAQ: OKYO logo small-cap
NASDAQ: OKYO

OKYO PHARMA LIMITED

$0.98 N/A 0% 7.9K

OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of DED and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. In addition to the recently completed Phase 2 trial of OK-101 to treat DED patients, OKYO is also evaluating OK-101 to treat NCP patients with the just announced opening of a Phase 2 trial to treat the debilitating conditions of NCP.

Investor Presentation

Sign Up For OKYO Email News Alerts

First Name*
Last Name*
Phone*
Email*

*I agree to receive communications by text message about updates related to companies and/or industries I’ve expressed interest in. You may opt out by replying STOP or reply HELP for more information. Message frequency varies. Message and data rates may apply. You may review our Privacy Policy to learn how your data is used.

Disclosure

RedChip Companies, Inc. research reports, company profiles, and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.

RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that RedChip Companies Inc. is an investor relations firm hired by certain companies to increase investor awareness to the small-cap equity community.

Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles, or in other investor relations materials or presentations that it publishes electronically or in print.

We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and/or the Ontario Securities Commission (“OSC”) at www.osc.gov.on.ca.

OKYO Pharma (OKYO) is a client of RedChip Companies. OKYO agreed to pay RedChip a one-time forty-four thousand dollar fee for a 10-day national TV ad campaign aired June 11 through June 25, 2024, a one-time twenty-thousand dollar fee for a five-day national TV ad campaign aired August 5 through August 9, 2024, and a one-time thirty-eight-thousand five-hundred dollar fee for a 10-day national TV ad campaign aired October 16 through October 29, 2024

Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services.